SKS
Susanne Katharina Schorsch
Amadeus Capital Partners
Partner
https://www.linkedin.com/in/susannekschorsch/
Description
Susanne joined Amadeus in 2023 and is a Partner in Amadeus’ European early-growth Deep Tech strategy.
She is a professional VC and angel investor since 2014 and has led and co-led more than 25 investments in Deep Tech including health and biotech.
Susanne was previously a Partner at Verve Ventures. She has served as board member or observer on several of her portfolio companies such as: CREAL, lightfield technology for VR and AR; antibody discovery platform MemoTherapeutics; high throughput organism-on-chip animal testing alternative Nagi Bioscience; retinal biomarker company Earlysight; breakthrough oral delivery system platform Biograil and next generation gene engineering company Somagenetix.
Further investments include commercial stage companies such as autonomous robotic indoor inspection market leader Flyability; AI assisted diagnostics provider Medimaps; as well as Wyden, as digital asset trading platform for institutionals.
Susanne’s exit track record includes social impact software player Alaya, (trade sale to Benevity in 2021), neuromodulation powerhouse Onward (IPO in 2021), IoT enabling nano-satellite company Astrocast (IPO in 2021), brain metabolism monitoring company Luciole (merged into Promedics in 2024), as well as financial fraud detection company NetGuardians (sale to PE in 2024).
Prior to her VC career, Susanne was a successful international business executive for 15 years. She headed BASF’s $1.4bn Global Additives Business and was responsible for Strategy and Innovation of BASF Performance Chemical Division.
Susanne has completed executive education programmes in Venture Capital and Innovation Organization at the UC Berkeley Haas School of Business. She holds an MSc and BSc in Industrial Engineering from the Karlsruhe Institute of Technology and is an alumna of the University of Pennsylvania's Wharton School.
Loading